Genome Engineering in Accelerating Discovery and Preclinical Applications

Genome Engineering in Accelerating Discovery and Preclinical Applications

Speaker: Dan (Xiaodan) Wang, Ph.D. Associate Director of Gene Targeting

• When CRISPR/Cas9 technology is applied to generate Genetically Modified Models, common challenges include transgene silencing, karyotype abnormalities, off-targeting risks, random integrations and mosaicism.
• To minimize the off-targeting effect and enhance the specificity, we design sgRNAs by combining the results from CCTop, Sanger and CrispRGold; The sgRNA is chosen based on UCA assay and other factors.
• Use of our CRISPR-based Extreme Genome Editing technology improves the efficiency of large fragment knock-in by up to 10-20 fold, meaning we can generate targeted cell lines, mouse and rat models in industry-leading timelines with a 98% success rate.